ARGX ArGEN-X SE

argenx to Present at Upcoming Investor Conferences

argenx to Present at Upcoming Investor Conferences



February 27, 2023



Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in several upcoming investor conferences in March:

  • Cowen 43rd Annual Healthcare Conference. Fireside chat on Monday, March 6, 2023 at 10:30 a.m. ET in Boston, MA.



  • Raymond James 44th Annual Institutional Investors Conference. Presentation on Tuesday, March 7, 2023 at 1:05 p.m. ET in Orlando, FL.



Additional information regarding these events will be available on the Investors section of the argenx website at .

About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first-and-only approved neonatal Fc receptor (FcRn) blocker in the U.S., the EU and Japan. For more information, visit and follow us on , , and .

For further information, please contact:

Media:

Kelsey Kirk

Investors:

Beth DelGiacco



EN
27/02/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ArGEN-X SE

Damien Choplain ... (+2)
  • Damien Choplain
  • Martial Descoutures
Damien Choplain ... (+2)
  • Damien Choplain
  • Martial Descoutures
Hilde Van Boxstael ... (+6)
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Michiel Declercq
  • Thomas Vranken
  • Wim Hoste
  • Wim Lewi

Morning Notes : ABI BB, ARGX BB, ATEB BB, CPINV BB, SOLB BB, CTPNV NA,...

: ABI BB, ARGX BB, ATEB BB, CPINV BB, SOLB BB, CTPNV NA, ZEAL DC, JDEP NA, MRUS US

ResearchPool Subscriptions

Get the most out of your insights

Get in touch